EUVIMEDEUVIMED entdecken
Crossref

Discovery of 4-Aminoquinazoline Derivatives as Potent PKMYT1 Inhibitors via Hydrogen Bond Donor-To-Acceptor Conversion for CCNE1 -Amplified Cancers

Haixiang Qi, Rui Lu, Yifei Zhu, Shuang Shang, Rongkai Xie, Junpu Ge, Li Sheng, Fang Hua, Heng Xu iD

Journal of Medicinal Chemistry · 22.10.2026 · 69 (20) · 23872-23897

DOI: 10.1021/acs.jmedchem.6c01446 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 05.10.2026. Verfasst von Haixiang Qi und 8 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Pek…. Hauptthemen laut MEDLINE: Cyclin E, Antineoplastic Agents, Quinazolines, Oncogene Proteins. Die Arbeit nennt 41 Literaturangaben. Gefördert von: Ministry of Education of the People's Republic of China, National Natural Science Foundation of China, National Science and Technology Major Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PKMYT1 is a critical regulator of the cell cycle and has emerged as a promising synthetic lethal target for CCNE1-amplified cancers. In this study, we report the design, synthesis, and biological evaluation of a novel series of 4-aminoquinazoline-based PKMYT1 inhibitors. A hydrogen bond donor-to-acceptor conversion strategy was successfully employed to reduce the hydrogen bond donor (HBD) count, thereby improving the drug-likeness of this series. Among them, compound 12f exhibited nanomolar inhibitory activity against PKMYT1 and potent antiproliferative activity in the OVCAR-3 ovarian cancer cell line. Furthermore, compound 12f demonstrated synergistic antiproliferative effects when combined with PARP inhibitors. Along with an acceptable oral pharmacokinetic profile, compound 12f demonstrated robust in vivo efficacy in OVCAR-3 xenograft models. Notably, compound 12f was well-tolerated, demonstrating no significant body weight loss or apparent toxicity to major organs. Collectively, these results underscore the therapeutic potential of compound 12f as a promising PKMYT1 inhibitor against CCNE1-amplified cancers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cyclin EAntineoplastic AgentsQuinazolinesOncogene ProteinsProtein Serine-Threonine KinasesMembrane ProteinsProtein Kinase InhibitorsOvarian NeoplasmsHumansAnimalsFemaleCell Line, TumorHydrogen BondingStructure-Activity RelationshipCell ProliferationMiceMice, NudeDrug DiscoveryXenograft Model Antitumor AssaysProtein-Tyrosine Kinases

Stichwörter der Autor:innen

CCNE1-amplified cancersPKMYT1 inhibitorshydrogen bondovarian cancerstructure-based drug design

Substanzen

Cyclin EAntineoplastic AgentsQuinazolinesOncogene ProteinsCCNE1 protein, humanPKMYT1 protein, humanProtein Serine-Threonine KinasesMembrane Proteins4-aminoquinazolineProtein Kinase Inhibitors

Autor:innen und Institutionen

  • State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing100050, China.
  • Beijing Key Laboratory of Small Molecule Immuno-Oncology Drug Discovery and Translational Development, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing100050, Chin…
  • Beijing Key Laboratory of New Drug Mechanisms and Pharmacological Evaluation Study (BZ0150), Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing100050, P. R. China.
  • State Key Laboratory Digestive Health, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing100050, P. R. China.

ORCID-Profile: Heng Xu

Förderung

  • Ministry of Education of the People's Republic of China
  • National Natural Science Foundation of China
  • National Science and Technology Major Project
  • Peking Union Medical College Hospital
  • Chinese Academy of Medical Sciences
  • Ministry of Education of the People’s Republic of China

Zitieren

APA

Qi, H., Lu, R., Zhu, Y., Shang, S., Xie, R., Ge, J., Sheng, L., Hua, F., & Xu, H. (2026). Discovery of 4-Aminoquinazoline Derivatives as Potent PKMYT1 Inhibitors via Hydrogen Bond Donor-To-Acceptor Conversion for CCNE1 -Amplified Cancers. Journal of Medicinal Chemistry, 69(20), 23872-23897. https://doi.org/10.1021/acs.jmedchem.6c01446

Vancouver

Qi H, Lu R, Zhu Y, Shang S, Xie R, Ge J, et al. Discovery of 4-Aminoquinazoline Derivatives as Potent PKMYT1 Inhibitors via Hydrogen Bond Donor-To-Acceptor Conversion for CCNE1 -Amplified Cancers. Journal of Medicinal Chemistry. 2026;69(20):23872-23897. doi:10.1021/acs.jmedchem.6c01446

BibTeX
@article{Qi2026,
  author = {Qi, Haixiang and Lu, Rui and Zhu, Yifei and Shang, Shuang and Xie, Rongkai and Ge, Junpu and Sheng, Li and Hua, Fang and Xu, Heng},
  title = {Discovery of 4-Aminoquinazoline Derivatives as Potent PKMYT1 Inhibitors via Hydrogen Bond Donor-To-Acceptor Conversion for CCNE1 -Amplified Cancers},
  journal = {Journal of Medicinal Chemistry},
  year = {2026},
  volume = {69},
  number = {20},
  pages = {23872--23897},
  doi = {10.1021/acs.jmedchem.6c01446}
}
Kostenlos starten →